Skip to content

Discovery of IMHDPA derivatives with selective cytotoxicity and autophagy-modulating properties: Structure-activity relationships and mechanistic insights.

Aug 2026 · European journal of medicinal chemistry · Vol 318, pp. 119197 · 0 citations · 44 references
Medicine

TL;DR

Findings establish IMHDPA derivatives as promising chemical probes for investigating the molecular basis of context-dependent autophagy-associated cytotoxicity and support future efforts aimed at elucidating the molecular determinants underlying this selective phenotype.

Abstract

Phenotypic drug discovery enables the identification of compounds with novel mechanisms of action and context-dependent biological activities that may not emerge from target-based approaches. Through high-content phenotypic screening, we identified the (E)-6-(2-((1H-indol-3-yl)methylene)hydrazineyl)-N,N-diethylpyrimidin-4-amine (IMHDPA) scaffold as a potent and highly selective inhibitor of HeLa cell proliferation. To further explore this scaffold, a library of 70 analogues was synthesized, and structure-activity relationship studies revealed stringent structural requirements for maintaining cellular potency and selectivity. Among them, compound 39 emerged as the most active derivative, exhibiting a GI50 value of 2.96 nM against HeLa cells and an exceptional selectivity index exceeding 16,000-fold across a panel of 15 cell lines. Compound 39 suppressed colony formation, migration, invasion, and spheroid growth, while inducing pronounced morphological alterations in HeLa cells. Mechanistic investigations indicated that its antiproliferative activity was associated with autophagy activation rather than apoptosis, necrosis, ferroptosis, or reactive oxygen species accumulation. Integrated transcriptomic and proteomic analyses implicated perturbation of cholesterol metabolism and inhibition of mTORC1 signaling as potential upstream events linked to autophagy induction. Collectively, these findings establish IMHDPA derivatives as promising chemical probes for investigating the molecular basis of context-dependent autophagy-associated cytotoxicity and support future efforts aimed at elucidating the molecular determinants underlying this selective phenotype.

View source

Similar papers

Aug 2026

Discovery of chromone-derived EGFR inhibitors as potent apoptosis inducers in cancer: In vitro and in vivo insights.

Compound 4v emerged as a leading candidate, showing EGFR kinase inhibitory activity comparable to Erlotinib, and computational analysis of 4v and EGFR molecular binding suggests that it serves as a superior binder to the inactive EGFR conformation.

Amr Elagamy, Mohamed S. Nafie, Ahmed Elnahrawy et al. · 0 citations
Aug 2026

Design, synthesis, and antitumor evaluation of celastrol derivatives targeting PRDX3.

In vivo efficacy evaluation demonstrated that 10d exhibited significantly superior tumor suppression in a subcutaneous xenograft model of H1975 tumors compared to celastrol, without causing notable systemic toxicity such as significant body weight loss.

Yu-Chi Zhao, Han-Shuang Cai, Li-Juan Zuo et al. · 0 citations
Sep 2026

Synthesis of Novel Benzoxazole–Piperazine Hybrids as Anticancer Leads: Biological, Molecular Docking, and ADMET Evaluations

The synthesized benzoxazole hybrid compounds showed promising anticancer activity with acceptable ADMET properties; however, further structural optimization and mechanistic studies are needed to validate the molecular targets and improve safety and pharmacokinetic profiles.

Mahmoud A. Al-Sha'er, A. H. Abdullah, Almeqdad Y. Habashneh et al. · 0 citations
Review Aug 2026

Mechanism and Molecular Target of Substituted Triazoles: A Therapeutic Strategy in Anticancer Drug Discovery.

This review is an attempt to bridge the gap between synthetic structural biology and translational oncology by systematically connecting the structure- activity relationships of novel triazole hybrids targeting Aromatase, VEGFR-2, IDO1, and Carbonic Anhydrase.

Yashika Jangra, S. Dev, P. Jain · 0 citations
Sep 2026

Discovery of quinoline-based derivatives as c-Met inhibitors for the treatment of non-small cell lung cancer.

The design, synthesis, and biological evaluation of a novel series of type II c-Met inhibitors bearing α-amino acid-derived linkers and a morpholinopropoxy quinoline scaffold position compound 41 as a promising lead for the development of next-generation, tolerable c-Met targeted therapeutics.

Zhong-Yuan Wang, Yi-Wei Zhang, Yun-Feng Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.